Список проголосовавших за комментарий " Biogen beats by $0.22, beats on revs (276.86)<ul><li>Reports Q1 (Mar) earnings of $5.20 per share, <strong>$0.22 <span style="color:#228822;">better than</span></strong> the Capital IQ Consensus of $4.98; revenues rose 3.1% year/year to $2.81 bln vs the $2.73 bln Capital IQ Consensus.</li><li>Product revenue highlights:<br/> <ul><li>TECFIDERA $958 mln +1% YoY</li><li>AVONEX $537 -5% YOY</li><li>PLEGRIDY $112 mln +5% YOY</li><li>TYSABRI $545 mln +14% YoY </li></ul></li><li>TYSABRI revenue grew 14% versus the prior year. Outside the U.S., TYSABRI revenues benefited by approximately $45 million due to reaching an agreement with the Price and Reimbursement Committee of the Italian National Medicines Agency (AIFA) related to TYSABRI sales in prior periods.</li><li>Versus Q4 2016, Biogen estimates TECFIDERA U.S. revenues were negatively impacted by approximately $50 million to $60 million due to lower inventory levels in the channel. Worldwide SPINRAZA revenues were $47 million.</li><li>«We are encouraged by the progress we made launching SPINRAZA in the U.S., and, following the positive CHMP opinion, we are ramping up pre-launch activities in Europe. The value this therapy provides to patients is compelling, and we are working to accelerate patient access globally,» Vounatsos continued. «Overall, I believe we're building positive momentum at the company, and I look forward to leading Biogen into a new and exciting era.»</li></ul>"